Is that “7.1% share of paid biologic prescriptions” figure for Tezspire (tezepelumab) correct?
Based on the information you provided, the claim is that Tezspire (tezepelumab) accounted for 7.1% of paid biologic prescriptions (TRx) in the U.S. from May 2023 through April 2024.
However, no supporting source or market-data report is included in your message, so I can’t verify the statistic or confirm the exact methodology (for example, whether “paid TRx” is restricted to outpatient pharmacy claims, uses a specific data vendor’s dataset, or includes particular biologic categories).
If you paste the link, report title, or the table/chart caption you’re referencing, I can help confirm whether the 7.1% figure matches the original market data.
Where do these “paid biologic prescriptions” market-share numbers usually come from?
Market-share figures of “paid TRx” are commonly reported by claims-data analytics vendors that track pharmacy transactions (e.g., prescriptions with a payment/processing status) and then calculate each brand’s share of total biologic prescription volume within a time window and geography. The exact number can change depending on:
- the specific biologic grouping used (all biologics vs. a disease-area subset),
- whether the measure includes only certain channels (retail/other),
- and how switching or rebills are handled.
How should you interpret a 7.1% TRx share?
A 7.1% share means Tezspire generated about 7.1% of the total number of paid biologic prescriptions during May 2023–April 2024, not necessarily:
- 7.1% of total sales revenue,
- 7.1% of patients,
- or 7.1% of market share by net price after rebates.
If you tell me what the report uses as the denominator (which biologics universe), I can help translate the figure into the most accurate interpretation.
Want me to verify it against a source?
If you share the market-data source (link, vendor name, or a screenshot/table caption), I can:
- confirm the 7.1% value,
- check that the dates match May 2023–April 2024,
- and restate the finding accurately with the correct context.
Sources cited: none (no market-data source was provided to verify the 7.1% figure).